Tandem Diabetes Care Reports Record Q4 and Strategic Shift
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Source: seekingalpha
Tandem Diabetes Care's stock surged by 35.75% as it reached a 20-day high, following the announcement of record Q4 results and a strategic shift in its business model.
The company reported Q4 revenue of $290 million, exceeding market expectations and marking a 15% year-over-year growth. This strong performance reflects robust market demand and a significant improvement in gross margins, which reached a historic high of 58%. Additionally, Tandem announced a transition to a pay-as-you-go reimbursement structure, which is expected to enhance long-term sustainability despite potential short-term impacts on sales.
The implications of these results indicate a strong foundation for future profitability and growth, as Tandem projects U.S. sales for 2026 to be between $730 million and $745 million. The strategic shift is seen as a proactive response to market changes, positioning the company favorably for continued expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNDM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNDM
Wall Street analysts forecast TNDM stock price to rise
18 Analyst Rating
8 Buy
10 Hold
0 Sell
Moderate Buy
Current: 15.400
Low
14.00
Averages
26.33
High
55.00
Current: 15.400
Low
14.00
Averages
26.33
High
55.00
About TNDM
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tandem Diabetes Care Receives EU CE Mark for Insulin Delivery Systems
- Market Expansion: Tandem Diabetes Care announced that its automated insulin delivery systems, t:slim X2 and Tandem Mobi, received the EU CE mark, allowing use in pregnant women with type 1 diabetes and adults with type 2 diabetes, significantly broadening its market applicability in Europe.
- Clinical Support: This approval is backed by data from the CIRCUIT trial, which showed that pregnant women using the t:slim X2 insulin pump experienced approximately 13% more time in the pregnancy glucose target range, providing strong clinical justification for its use in type 1 diabetes during pregnancy.
- Efficacy Validation: The 2IQP trial demonstrated that patients using the t:slim X2 pump had about a 1% decline in the diabetes biomarker A1C, compared to a 0.3% drop in those continuing their existing insulin regimen, further supporting its indication for type 2 diabetes patients.
- Product Launch Plans: The t:slim X2 insulin pump is already available in several European countries, while the Tandem Mobi system is expected to launch in select markets in the second half of 2026, indicating the company's proactive approach to product promotion and market penetration.
See More
Tandem Diabetes Receives CE Mark for Expanded Indications
- Expanded Indications: Tandem Diabetes Care announced that its t:slim X2 and Tandem Mobi systems received CE mark approval for use in pregnant individuals with type 1 diabetes and adults with type 2 diabetes, highlighting the company's commitment to innovation in diabetes technology.
- Clinical Trial Results: Based on the CIRCUIT trial findings, participants with type 1 diabetes during pregnancy using Control-IQ technology spent 12.6% more time in the target glucose range, approximately 3 hours more per day compared to standard therapy, significantly improving glycemic control during pregnancy.
- Type 2 Diabetes Study: In the 2IQP trial, patients using Control-IQ+ technology achieved a 0.9% reduction in A1C, compared to 0.3% in the control group, demonstrating the effectiveness and safety of this technology across diverse populations with type 2 diabetes.
- Market Outlook: The Tandem Mobi system is expected to launch in select European countries in the second half of 2026, further expanding market share and enhancing the company's competitive position in the global diabetes management landscape.
See More
Tandem Diabetes Care Upgraded by Wells Fargo Amid Positive PAYGO Model Outlook
- Stock Surge: Tandem Diabetes Care (TNDM) saw a ~14% increase in afternoon trading on Monday, primarily driven by an upgrade from Wells Fargo, indicating strong market confidence in its future performance.
- Rating Upgrade: Wells Fargo raised Tandem's rating from equal-weight to overweight and increased its target price from $21 to $27, suggesting a ~57% upside, reflecting analysts' optimistic outlook on the company's new business model.
- Advantages of PAYGO Model: Analyst Larry Biegelsen highlighted that Tandem's pay-as-you-go (PAYGO) pharmacy model offers low upfront costs, and management expressed confidence in growing new starts in the U.S., indicating better-than-expected market acceptance of this model.
- Future Catalysts: The Mobi Tubeless product is seen as a near-term catalyst expected to drive margin improvement, further solidifying Tandem's competitive position in the insulin pump market.
See More
Latest Rating Changes on Wall Street
- Executive Rating Updates: Goldman Sachs initiates coverage on HawkEye 360 with a Buy rating, emphasizing its status as a profitable RF signals intelligence satellite operator, which is expected to achieve substantial revenue and earnings growth, reflecting strong confidence in its market potential.
- Dell Rating Upgrade: Morgan Stanley upgrades Dell from Underweight to Equal Weight, admitting prior market expectations were incorrect, highlighting Dell's superior supply chain management and execution compared to peers, enabling effective capture of critical demand and market share gains.
- MedTech Company Upgrade: Wells Fargo upgrades Tandem Diabetes Care to Overweight, citing an attractive risk/reward profile in the medical technology sector, indicating optimism about its future growth potential.
- Microsoft Market Performance Initiation: Citizens initiates Microsoft with a Market Outperform rating and a $550 price target, reflecting strong market performance potential despite a 7% decline year-to-date, indicating resilience in its business model.
See More
Paradice Investment Management Takes $17.64 Million Stake in McGrath RentCorp
- New Investment Disclosure: Paradice Investment Management disclosed a new position in McGrath RentCorp (NASDAQ:MGRC) on May 14, 2026, acquiring 158,670 shares valued at approximately $17.64 million, indicating strong confidence in the company.
- Market Performance Analysis: Despite MGRC shares declining 4% over the past year, the company's ongoing expansion in the rental business and its impressive 35-year dividend growth streak highlight its stability and attractiveness in the industry.
- Financial Health Status: In the first quarter, MGRC reported a 2% increase in total revenue to $198.5 million and a 5% rise in rental revenue to $162.2 million, demonstrating resilience and growth potential amid economic uncertainty.
- Future Outlook: MGRC reaffirmed its full-year revenue guidance of up to $995 million and adjusted EBITDA of up to $378 million, suggesting that if rental demand remains strong, the current valuation may appear more attractive than recent share performance indicates.
See More
Tandem Diabetes Exceeds Q1 Revenue Expectations
- Revenue Growth: Tandem Diabetes Care reported Q1 2026 revenue of $247.2 million, reflecting a 5.5% year-on-year increase that surpassed analyst expectations of $239.6 million, indicating strong market performance.
- Profitability Improvement: The GAAP loss per share was $0.30, better than the expected $0.44 loss, while adjusted EBITDA reached $2.73 million with a 103% year-on-year growth, showcasing significant operational efficiency gains.
- Strategic Transition: The company reaffirmed its full-year revenue guidance of $543 million, which is 49.5% below analyst estimates; however, management emphasized that the rollout of the PayGo pharmacy model will be a central growth driver moving forward.
- International Expansion: Tandem launched direct commercial operations in the UK, Switzerland, and Austria, which is expected to improve average selling prices and drive margin gains, with early feedback indicating strong potential in international markets.
See More
Tandem Diabetes Care Receives EU CE Mark for Insulin Delivery Systems
- Market Expansion: Tandem Diabetes Care announced that its automated insulin delivery systems, t:slim X2 and Tandem Mobi, received the EU CE mark, allowing use in pregnant women with type 1 diabetes and adults with type 2 diabetes, significantly broadening its market applicability in Europe.
- Clinical Support: This approval is backed by data from the CIRCUIT trial, which showed that pregnant women using the t:slim X2 insulin pump experienced approximately 13% more time in the pregnancy glucose target range, providing strong clinical justification for its use in type 1 diabetes during pregnancy.
- Efficacy Validation: The 2IQP trial demonstrated that patients using the t:slim X2 pump had about a 1% decline in the diabetes biomarker A1C, compared to a 0.3% drop in those continuing their existing insulin regimen, further supporting its indication for type 2 diabetes patients.
- Product Launch Plans: The t:slim X2 insulin pump is already available in several European countries, while the Tandem Mobi system is expected to launch in select markets in the second half of 2026, indicating the company's proactive approach to product promotion and market penetration.
See More
Tandem Diabetes Receives CE Mark for Expanded Indications
- Expanded Indications: Tandem Diabetes Care announced that its t:slim X2 and Tandem Mobi systems received CE mark approval for use in pregnant individuals with type 1 diabetes and adults with type 2 diabetes, highlighting the company's commitment to innovation in diabetes technology.
- Clinical Trial Results: Based on the CIRCUIT trial findings, participants with type 1 diabetes during pregnancy using Control-IQ technology spent 12.6% more time in the target glucose range, approximately 3 hours more per day compared to standard therapy, significantly improving glycemic control during pregnancy.
- Type 2 Diabetes Study: In the 2IQP trial, patients using Control-IQ+ technology achieved a 0.9% reduction in A1C, compared to 0.3% in the control group, demonstrating the effectiveness and safety of this technology across diverse populations with type 2 diabetes.
- Market Outlook: The Tandem Mobi system is expected to launch in select European countries in the second half of 2026, further expanding market share and enhancing the company's competitive position in the global diabetes management landscape.
See More
Tandem Diabetes Care Upgraded by Wells Fargo Amid Positive PAYGO Model Outlook
- Stock Surge: Tandem Diabetes Care (TNDM) saw a ~14% increase in afternoon trading on Monday, primarily driven by an upgrade from Wells Fargo, indicating strong market confidence in its future performance.
- Rating Upgrade: Wells Fargo raised Tandem's rating from equal-weight to overweight and increased its target price from $21 to $27, suggesting a ~57% upside, reflecting analysts' optimistic outlook on the company's new business model.
- Advantages of PAYGO Model: Analyst Larry Biegelsen highlighted that Tandem's pay-as-you-go (PAYGO) pharmacy model offers low upfront costs, and management expressed confidence in growing new starts in the U.S., indicating better-than-expected market acceptance of this model.
- Future Catalysts: The Mobi Tubeless product is seen as a near-term catalyst expected to drive margin improvement, further solidifying Tandem's competitive position in the insulin pump market.
See More
Latest Rating Changes on Wall Street
- Executive Rating Updates: Goldman Sachs initiates coverage on HawkEye 360 with a Buy rating, emphasizing its status as a profitable RF signals intelligence satellite operator, which is expected to achieve substantial revenue and earnings growth, reflecting strong confidence in its market potential.
- Dell Rating Upgrade: Morgan Stanley upgrades Dell from Underweight to Equal Weight, admitting prior market expectations were incorrect, highlighting Dell's superior supply chain management and execution compared to peers, enabling effective capture of critical demand and market share gains.
- MedTech Company Upgrade: Wells Fargo upgrades Tandem Diabetes Care to Overweight, citing an attractive risk/reward profile in the medical technology sector, indicating optimism about its future growth potential.
- Microsoft Market Performance Initiation: Citizens initiates Microsoft with a Market Outperform rating and a $550 price target, reflecting strong market performance potential despite a 7% decline year-to-date, indicating resilience in its business model.
See More
Paradice Investment Management Takes $17.64 Million Stake in McGrath RentCorp
- New Investment Disclosure: Paradice Investment Management disclosed a new position in McGrath RentCorp (NASDAQ:MGRC) on May 14, 2026, acquiring 158,670 shares valued at approximately $17.64 million, indicating strong confidence in the company.
- Market Performance Analysis: Despite MGRC shares declining 4% over the past year, the company's ongoing expansion in the rental business and its impressive 35-year dividend growth streak highlight its stability and attractiveness in the industry.
- Financial Health Status: In the first quarter, MGRC reported a 2% increase in total revenue to $198.5 million and a 5% rise in rental revenue to $162.2 million, demonstrating resilience and growth potential amid economic uncertainty.
- Future Outlook: MGRC reaffirmed its full-year revenue guidance of up to $995 million and adjusted EBITDA of up to $378 million, suggesting that if rental demand remains strong, the current valuation may appear more attractive than recent share performance indicates.
See More
Tandem Diabetes Exceeds Q1 Revenue Expectations
- Revenue Growth: Tandem Diabetes Care reported Q1 2026 revenue of $247.2 million, reflecting a 5.5% year-on-year increase that surpassed analyst expectations of $239.6 million, indicating strong market performance.
- Profitability Improvement: The GAAP loss per share was $0.30, better than the expected $0.44 loss, while adjusted EBITDA reached $2.73 million with a 103% year-on-year growth, showcasing significant operational efficiency gains.
- Strategic Transition: The company reaffirmed its full-year revenue guidance of $543 million, which is 49.5% below analyst estimates; however, management emphasized that the rollout of the PayGo pharmacy model will be a central growth driver moving forward.
- International Expansion: Tandem launched direct commercial operations in the UK, Switzerland, and Austria, which is expected to improve average selling prices and drive margin gains, with early feedback indicating strong potential in international markets.
See More
